1-hydroxy-4-methylamino-adamantane | 75375-90-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-hydroxy-4-methylamino-adamantane
• 英文别名: 1-hydroxy-4-methylaminoadamantane；E-4-(methylamino)adamantan-1-ol；4-methylamino-adamantan-1-ol；4-methylaminoadamantan-1-ol；4-(methylamino)adamantan-1-ol
• CAS: 75375-90-5
• 化学式: C₁₁H₁₉NO
• 分子量: 181.278
• InChiKey: OXOBSRVVNMKQNB-UHFFFAOYSA-N

物化性质

• 沸点：
  284.4±33.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-hydroxy-4-methylamino-adamantane 、 (2,4-dichloro-phenoxy-methylsulfanyl)-acetic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 2-(2,4-dichloro-phenoxymethylsulfanyl)-N-(5-hydroxy-adamantan-2-yl)-N-methyl-acetamide
  参考文献：
  名称：

  WO2008/134221

  摘要：

  公开号：
• 作为产物：
  描述：

  5-羟基-2-金刚烷酮 在 palladium 10% on activated carbon lithium aluminium tetrahydride 、 甲酸铵 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 10.0h， 生成 1-hydroxy-4-methylamino-adamantane
  参考文献：
  名称：

  WO2008/101914

  摘要：

  公开号：

文献信息

• TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：Crespin Olivier

  公开号：US20120165337A1

  公开（公告）日：2012-06-28

  The invention relates to compounds of formula (I), where: A is a bond, an oxygen atom, or an -CH 2 — group; Ar 1 is a phenyl or heteroaryl group; Ar 2 is a phenyl, heteroaryl, or heterocycloalkyl group; R 1a,b,c and R2a,b,c are a hydrogen or halogen atom, or an alkyl, cycloalkyl, or lkyl-cycloalkyl group optionally substituted by one or more halogen atoms, or an —OR 5 (hydroxy or alkoxy), hydroxy-alkyl, alkoxy-alkyl, alkoxy-alkoxy, halogenoalkyl, —O-halogenoalkyl, oxo, —CO-alkyl, —CO-alkyl-NR 6 R 7 , —CO-halogenoalkyl, —COOR 5 , alkyl-COOR 5 , —O-alkyl-COOR 5 , —SO 2 -alkyl, —SO 2 -cycloalkyl, —SO 2 -alkyl-cycloalkyl, —SO 2 -alkyl-OR 5 , —SO 2 -alkyl-COOR 5 , —SO 2 -alkyl-NR 6 R 7 , —SO 2 -halogenoalkyl, alkyl-SO 2 -alkyl, —SO 2 —NR 6 R 7 , —SO 2 -alkyl-O-alkyl-OR 5 , —CONR 6 R 7 , -alkyl-CONR 6 R 7 , or -alkyl-NR 6 R 7 group, or further R 1a , R 1b , and R 1c are bonded to R 2a , R 2b , R 2c , respectively, as well as to the carbon atom having same, and are -alkyl-O—; R 3 is a hydrogen atom or an alkyl group; R 4 is a ONR 6 R 7 group, a hydroxyalkyl group substituted by a halogenoalkyl group, or an lkyl-NH—SO 2 -alkyl, NH—SO 2 -alkyl, —O—SO 2 —NR 6 R 7 , -alkyl-CO—NR 6 R 7 , —O-alkyl-CO—NR 6 R 7 , -alkyl-NR 6 R 7 , —O—CO—NR 6 R 7 , -alkyl-heteroaryl, a heteroaryl group optionally substituted by an alkyl, alkoxy-imino, or —NH—NH—CO-alkyl group, with the proviso that R 4 is in the cis position when it is the ONR 6 R 7 group and that R 6 and R 7 are each hydrogen, or an lkyl or lkyl-phenyl group; R 5 is hydrogen, an lkyl group, or lkyl-phenyl; R 6 and R 7 , identical or different, are each a hydrogen atom, an alkyl group, alkoxy, or an alkyl-phenyl group; and R 8 is a hydrogen atom or an O 2 -alkyl group, or a group of formula -Het, where B can be absent or be a bond, an oxygen atom, or a O— or O 2 —(CH 2 ) n group, with n being equal to 0, 1, or 2, and where Het is a heteroaryl or heterocycloaryl optionally substituted by the alkyl, —SO 2 -alkyl, and —COOR 5 groups. The invention also relates to a method for preparing same to the therapeutic use thereof.

  该发明涉及式(I)的化合物，其中：A是键合，氧原子，或-CH2-基团；Ar1是苯基或杂环芳基；Ar2是苯基，杂环芳基，或杂环烷基基团；R1a，b，c和R2a，b，c是氢原子或卤素原子，或烷基，环烷基，或烷基-环烷基基团，可选择地被一个或多个卤素原子取代，或-OR5（羟基或烷氧基），羟基-烷基，烷氧基-烷基，烷氧基-烷氧基，卤代烷基，-O-卤代烷基，酮基，-CO-烷基，-CO-烷基-NR6R7，-CO-卤代烷基，-COOR5，烷基-COOR5，-O-烷基-COOR5，-SO2-烷基，-SO2-环烷基，-SO2-烷基-环烷基，-SO2-烷基-OR5，-SO2-烷基-COOR5，-SO2-烷基-NR6R7，-SO2-卤代烷基，烷基-SO2-烷基，-SO2-NR6R7，-SO2-烷基-O-烷基-OR5，-CONR6R7，-烷基-CONR6R7，或-烷基-NR6R7基团，或进一步R1a，R1b和R1c与R2a，R2b，R2c分别键合到相同的碳原子，并且是-烷基-O-；R3是氢原子或烷基基团；R4是ONR6R7基团，一个被卤代烷基取代的羟基烷基基团，或烷基-NH-SO2-烷基，NH-SO2-烷基，-O-SO2-NR6R7，-烷基-CO-NR6R7，-O-烷基-CO-NR6R7，-烷基-NR6R7，-O-CO-NR6R7，-烷基-杂环芳基，一个可选择地被烷基，烷氧基亚胺，或-NH-NH-CO-烷基基团取代的杂环芳基，但R4在ONR6R7基团时处于顺式位置，并且R6和R7各自是氢，或烷基或烷基-苯基；R5是氢，烷基基团，或烷基-苯基；R6和R7，相同或不同，各自是氢原子，烷基基团，烷氧基，或烷基-苯基；R8是氢原子或O2-烷基基团，或式-Het的基团，其中B可以不存在或是键合，氧原子，或O-或O2-(CH2)n基团，其中n等于0，1或2，而Het是一个可选择地被烷基，-SO2-烷基，和-COOR5基团取代的杂环芳基或杂环烷基。该发明还涉及制备这些化合物的方法以及它们的治疗用途。
• 11BETA-HSD1 ACTIVE COMPOUNDS
  申请人：Ebdrup Soren

  公开号：US20100056600A1

  公开（公告）日：2010-03-04

  A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

  本文描述了一类通式为(I)的新化合物，它们在治疗中的应用，包括含有这些化合物的药物组合物，以及它们在制造药物中的应用。这些化合物调节11β-羟基类固醇脱氢酶1型（11βHSD1）的活性，因此在治疗调节该酶活性有益的疾病，如代谢综合征中有用。
• PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES
  申请人：Kilburn John Paul

  公开号：US20090306048A1

  公开（公告）日：2009-12-10

  A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

  本文描述了一类新型化合物的一般式（I），它们在治疗中的应用，包括这些化合物的制药组合物以及它们在药物制造中的应用。这些化合物调节11β-羟基类固醇脱氢酶1（11βHSD1）的活性，因此在治疗这种调节有益的疾病（例如代谢综合症）中有用。
• TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
  申请人：Braun Alain Jean

  公开号：US20120245148A1

  公开（公告）日：2012-09-27

  The present invention relates to tetrahydroquinoxaline urea derivatives, to their preparation and to their therapeutic application.

  本发明涉及四氢喹喔啉脲衍生物，其制备方法及其治疗应用。
• PHARMACEUTICAL USE OF SUBSTITUTED AMIDES
  申请人：Ebdrup Soren

  公开号：US20100087543A1

  公开（公告）日：2010-04-08

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydro-genase type 1 (11βHSD1) and the use of these compounds as pharmaceutical composi-tions, are described. Also a novel class of substituted amides, their use in therapy, phar-maceutical compositions comprising the compounds, as well as their use in the manufac-ture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active gluco-corticoid is desirable.

  本文描述了使用取代酰胺来调节11β-羟基类固醇脱氢酶1型（11βHSD1）的活性以及这些化合物作为药物组合物的用途。还描述了一类新型的取代酰胺，它们在治疗中的用途，包括这些化合物的药物组合物以及它们在制造药物方面的用途。这些化合物是11βHSD1活性的调节剂，更具体地说是抑制剂，可能在治疗一系列需要降低活性糖皮质激素细胞内浓度的医学疾病中有用。